Featured pricing is subject to change. If you’re struggling with dry skin, we don’t have to tell you twice: the best cleansers can make a difference. It’s not just about removing impurities ...

Obesity-drug developer BioAge Labs Inc. held on to a slim gain at the closing bell and natural-gas producer BKV Corp. ended flat Thursday, the day the two initial public offerings debuted.

Kristen Fortney, cofounder and CEO of BioAge Labs. From the San Francisco Business Times. BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of shares on offer by 40%. The expansion of the listing reflects the massive ...

Promise. Almost every single dermatologist recommends the La Roche-Posay Effaclar Medicated Gel Cleanser. Dr. Chen explains that this gel cleanser uses salicylic acid and lipo-hydroxy acid to ...

Learn more The Bioré Deep Pore Charcoal Cleanser was put on my radar sometime in my middle school days when I was a pimple-prone teen. Now, at 27 years old, I'm just as committed to using it as I ...

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human ...

Want to introduce a new cleanser into your routine? Try a water-based cleanser. Here’s what you need to know about them. When it comes to skincare, the choice is often overwhelming. The steps ...

Facial cleansers are the unsung heroes of skincare. They lay the foundation for your entire routine, cleansing away ...

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...

Earlier this week, BioAge said in a filing it was looking to offer 10.5M shares priced between $17 and $19 per share.The ...

BioAge Labs, Inc. (BIOA) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung’s rating is based on several promising developments at BioAge Labs, Inc ...